Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UDP glucuronosyltransferase 2 family, polypeptide B7 pseudogene (ENSG00000250642) is a pseudogene belonging to the UDP-glucuronosyltransferase (UGT) 2 family. Pseudogenes such as this are nonfunctional copies or fragments of genes that typically do not encode functional protein products. They are identified based on sequence similarity to known functional UGT family members but generally lack biological or therapeutic activity and are not considered valid drug targets in biomedical research. Pseudogenes may occasionally have regulatory genomic roles but are not classified as receptors, enzymes, transporters, or other classical drug targets[3][5]. Detailed notes: - This entry is a pseudogene, not a protein-coding gene, enzyme, receptor, or other recognized molecular target. - Pseudogenes may be annotated similarly to protein-coding UGT2 family members, but they do not produce a functional protein, and there is no known evidence for their expression or biological activity as a protein. Therefore, it is not a therapeutic target, and its designation as a target is incorrect. - There are no known drugs, mechanisms of action, biomarkers, or safety concerns relevant to this pseudogene, and it has not been implicated in disease or biological pathways in the same way as true UGT2 enzymes. - Functional UGT2 enzymes (such as UGT2A2, UGT2B7) are involved in drug and xenobiotic metabolism, but this does not apply to detected pseudogenes[2][3][5]. Summary: This is a detected pseudogene related to the UDP-glucuronosyltransferase 2 family. It is not a functional gene product and should not be considered a therapeutic target. Its use as a molecular target is incorrect.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UDP glucuronosyltransferase 2 family, polypeptide B7 pseudogene.